These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37680628)

  • 1. Development of a bivalent protein-based vaccine candidate against invasive pneumococcal diseases based on novel pneumococcal surface protein A in combination with pneumococcal histidine triad protein D.
    Afshari E; Ahangari Cohan R; Shams Nosrati MS; Mousavi SF
    Front Immunol; 2023; 14():1187773. PubMed ID: 37680628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants.
    Malekan M; Siadat SD; Aghasadeghi M; Shahrokhi N; Afrough P; Behrouzi A; Ahmadi K; Mousavi SF
    J Med Microbiol; 2020 Mar; 69(3):465-477. PubMed ID: 32100705
    [No Abstract]   [Full Text] [Related]  

  • 3. A new candidate epitope-based vaccine against PspA PhtD of
    Shafaghi M; Bahadori Z; Barzi SM; Afshari E; Madanchi H; Mousavi SF; Shabani AA
    Front Cell Infect Microbiol; 2023; 13():1271143. PubMed ID: 38035337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.
    Ochs MM; Williams K; Sheung A; Lheritier P; Visan L; Rouleau N; Proust E; de Montfort A; Tang M; Mari K; Hopfer R; Gallichan S; Brookes RH
    Hum Vaccin Immunother; 2016 Nov; 12(11):2946-2952. PubMed ID: 27392182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism.
    Visan L; Rouleau N; Proust E; Peyrot L; Donadieu A; Ochs M
    Hum Vaccin Immunother; 2018 Feb; 14(2):489-494. PubMed ID: 29135332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.
    Brookes RH; Ming M; Williams K; Hopfer R; Gurunathan S; Gallichan S; Tang M; Ochs MM
    Hum Vaccin Immunother; 2015; 11(7):1836-9. PubMed ID: 25912273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis.
    André GO; Borges MT; Assoni L; Ferraz LFC; Sakshi P; Adamson P; Gordon DL; Ogunniyi AD; Venter H; Converso TR; Darrieux M
    Vaccine; 2021 Jun; 39(27):3626-3632. PubMed ID: 34045100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
    Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
    PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy.
    Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC
    Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with PhtD truncated fragments reduces nasopharyngeal colonization by Streptococcus pneumoniae.
    André GO; Assoni L; Rodriguez D; Leite LCC; Dos Santos TEP; Ferraz LFC; Converso TR; Darrieux M
    Vaccine; 2020 May; 38(26):4146-4153. PubMed ID: 32362528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Foster-Nyarko E; Owiafe PK; Ceesay F; Worwui A; Idoko OT; Owolabi O; Bojang A; Jarju S; Drammeh I; Kampmann B; Greenwood BM; Alderson M; Traskine M; Devos N; Schoonbroodt S; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2017 May; 35(19):2531-2542. PubMed ID: 28389097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-silico design and evaluation of an epitope-based serotype-independent promising vaccine candidate for highly cross-reactive regions of pneumococcal surface protein A.
    Afshari E; Cohan RA; Sotoodehnejadnematalahi F; Mousavi SF
    J Transl Med; 2023 Jan; 21(1):13. PubMed ID: 36627666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.
    Verhoeven D; Perry S; Pichichero ME
    Clin Vaccine Immunol; 2014 Aug; 21(8):1037-45. PubMed ID: 24850621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
    Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection.
    Huang J; Gingerich AD; Royer F; Paschall AV; Pena-Briseno A; Avci FY; Mousa JJ
    Infect Immun; 2021 Apr; 89(5):. PubMed ID: 33649050
    [No Abstract]   [Full Text] [Related]  

  • 20. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
    Denoël P; Philipp MT; Doyle L; Martin D; Carletti G; Poolman JT
    Vaccine; 2011 Jul; 29(33):5495-501. PubMed ID: 21624422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.